Alcohol Misuse, Gut Microbial Dysbiosis and PrEP Care Continuum: Application and Efficacy of SBIRT Intervention

Launched by SHIRISH S BARVE · Aug 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how a specific intervention called SBIRT (Screening, Brief Intervention, and Referral to Treatment) can help reduce alcohol misuse among people using PrEP, a medication that helps prevent HIV infections. The researchers want to learn how alcohol use affects adherence to PrEP—meaning how well people stick to taking their medication—and how early support can make a difference. They will also look at how alcohol use impacts gut health and overall inflammation in the body.

To participate in this study, individuals must be between the ages of 18 and 85, be confirmed as HIV-negative, and currently using PrEP. They should be able to understand and communicate in English or Spanish and be mentally capable of giving their consent. Participants will be involved in activities that assess their alcohol use and health, and they can expect support and guidance throughout the process. It's important to know that certain medical conditions or medications might exclude someone from participating. If you're interested or think you might qualify, reaching out to the healthcare facility involved could be a good next step.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18-85 years
• • Confirmation of seronegative HIV, Hep B, and Hep C status
• • PrEP users
• • English-speaking or Spanish speaking
• • Cognitively competent to provide consent
• • Attend a participating healthcare facility
• Exclusion Criteria:
• • Inability to consent
• • Existing diagnosis of major psychiatric illness
• • Unstable medical conditions (e.g., cancer)
• • Taking immunosuppressants or Chemotherapy
• • Taking daily antibiotics or probiotics
• • Severe gastrointestinal/liver disease
• • Autoimmune disease